Libtayo® (cemiplimab-rwlc) presentations at asco highlight expanding clinical data in diverse cancers

Tarrytown, n.y., may 19, 2021 /prnewswire/ --  presentations include first positive clinical data for the fianlimab (lag-3 inhibitor) and libtayo combination in advanced melanoma regeneron will host an investor webcast on monday, june 7 to provide further updates across its oncology portfolio regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the company will share a range of presentations for its pd-1 inhibitor libtayo® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 american society of clinical oncology (asco) annual meeting from june 4-8, taking place virtually.
REGN Ratings Summary
REGN Quant Ranking